CompletedPhase 2NCT02050919
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Studying Pleomorphic rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OHSU Knight Cancer Institute
- Principal Investigator
- Christopher RyanOHSU Knight Cancer Institute
- Intervention
- Epirubicin Hydrochloride(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2020
Study locations (1)
- OHSU Knight Cancer Institute, Portland, Oregon, United States
Collaborators
Bayer · Oregon Health and Science University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02050919 on ClinicalTrials.gov